Market research
24OA.F Obalon Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -1.24
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -1.24
About
About Obalon Therapeutics, Inc
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 24OA.F discussion.
5 years, 5 months ago
Obalon Therapeutics, Inc is currently in a long term uptrend where the price is trading 20.7% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.9.
Obalon Therapeutics, Inc's total revenue sank by 92.2% to $61K since the same quarter in the previous year.
Its net income has increased by 73.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 68.0% to $-2M since the same quarter in the previous year.
Based on the above factors, Obalon Therapeutics, Inc gets an overall score of 4/5.